Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 4,695

Document Document Title
WO/2020/184670A1
The present invention relates to a method for monodeuterated lower alkylating an amine moiety of a compound which contains an amine that is protected by an aralkyl group, wherein a monodeuterated lower alkyl is introduced into the amine ...  
WO/2020/180624A1
Compounds are provided having the structure of Formula (I): or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein A, X1, X2, Q, R1, R2 and n are as defined herein. Such compounds function ...  
WO/2020/173016A1
The present invention relates to a resorcinol dianisole derivative, wherein the chemical structure of this compound is as represented by the following formula (I). The compound of the present invention can inhibit the binding of programm...  
WO/2020/173346A1
The present invention relates to the pharmaceutical and chemical field, and provided is a method for preparing siponimod. The method of the present invention relates to taking 3-bromo-4-methylacetophenone as a starting material, and perf...  
WO/2020/174408A1
The present application provides novel polymorphic forms of siponimod, their processes, their use in purification of other crystalline polymorphic forms of siponimod, and pharmaceutical compositions containing them. The present applicati...  
WO/2020/175392A1
A compound which has a molecular weight of 3,000 or less, while having a partial structure that is represented by formula (X). (In formula (X), ring W1 represents a ring structure that does not have aromaticity, while having at least one...  
WO/2020/175393A1
A compound represented by general formula (I). [In formula (I), R3, R4, and R5 each independently represent an electron-attracting group. R1, R2, R6, and R7 each independently represent a hydrogen atom, a heterocyclic group, a halogen at...  
WO/2020/161632A1
The present application provides novel polymorphic forms of siponimod, their processes, their use in purification of other crystalline polymorphic forms of siponimod, and pharmaceutical compositions containing them. The present applicati...  
WO/2020/156359A1
Disclosed in the present invention are a quaternary ammonium salt compound and a preparation method therefor and a use thereof, relating to the field of medicinal chemistry. Disclosed in the present invention is the compound shown in for...  
WO/2020/159824A1
Provided herein are pharmaceutical compositions comprising compounds that inhibit Factor XIa or kallikrein and methods of use thereof.  
WO/2020/154250A1
Disclosed is method for converting a beta-lactam antibiotic into a "masked" beta- lactam antibiotic to permit it to cross the waxy cuticle of a plant and then subsequently unmasking the beta-lactam and converting it into an active beta-l...  
WO/2019/231933A3
The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds and methods of making and using such compounds.  
WO/2020/146568A1
A method for the synthesis of diazabicyclo[6.2.0]decane compounds is provided. The synthesis proceeds by stereoselective synthesis of a chiral lactone followed by azetidine formation via a series of chemoselective reactions. Bicyclizatio...  
WO/2020/142742A1
Compounds and compositions for modulating fibroblast activation protein (FAP) are described. The compounds and compositions may find use as therapeutic agents for the treatment of diseases, including hyperproliferative diseases.  
WO/2020/114477A1
The present invention relates to a compound represented by the formula (II), the pharmaceutically acceptable salt thereof, and the uses of the compound acting as an S1P1 agonist.  
WO/2020/118041A1
The disclosure provides ionizable amine lipids and salts thereof (e.g., pharmaceutically acceptable salts thereof) useful for the delivery of biologically active agents, for example delivering biologically active agents to cells to prepa...  
WO/2020/109434A1
The present invention relates to compounds of formula (I), to processes for producing the compounds, and to electronic devices containing at least one compound of formula (I).  
WO/2020/103884A1
Amides that inhibit cellular necrosis and/or human receptor interacting protein 1 kinase (RIP1), including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrates and stereoisomers thereof. The compounds are employed ...  
WO/2020/104930A1
The present invention relates to an improved asymmetric synthesis of azaspiro or di- azaspiro compound (hereafter referred to as the compound 5, (5A) or (5N)) or their pharmaceutically acceptable salts and derivatives; through the format...  
WO/2020/104822A1
The present invention relates to a compound of formula (Ia), or a pharmaceutically acceptable salt or hydrate thereof, wherein: the group X-Y is -NHSO2- or -SO2NH-; R1 is H or alkyl; R2 is selected from COOH and a tetrazolyl group; R3 is...  
WO/2020/098710A1
Provided in the present application are a substituted bis-aryl amide compound and a preparation method and an application therefor, the substituted bis-aryl amide compound or a pharmaceutically acceptable salt thereof having the structur...  
WO/2020/080979A1
This disclosure relates to new phthalimide and isoindolinone derivatives and other PFKFB3 inhibitors for use in the treatment of diseases. The invention further relates to pharmaceutical compositions containing such PFKFB3 inhibitors, me...  
WO/2020/074489A1
The present invention relates to compounds of Formula (I), wherein R1, R2, R3, R4 and G are as defined herein. The invention further relates to herbicidal compositions which comprise a compound of Formula (I), to their use for controllin...  
WO/2020/039092A3
The present invention comprises novel aromatic molecules, which can be used in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders such as disorders of the haemat...  
WO/2020/039088A3
The present invention comprises novel aromatic molecules, which can be used in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders such as disorders of the haemat...  
WO/2020/056553A1
The invention belongs to the field of organic chemistry, and particularly relates to a method for preparing a heterocyclic compound represented by formula I and salts thereof. Compared with the prior art, the invention avoids the use of ...  
WO/2020/052647A1
Involved are a class of spiro-heterocyclic compounds which can act as lysine-specific demethylase 1 (LSD1) inhibitors, and the use of same in the preparation of drugs for treating LSD1-related diseases. Specifically involved are a compou...  
WO/2020/047991A1
Use of an anti-acarid additive in daily chemical products. Diaryl lactam compounds have excellent anti-acarid effects, and can be used in applications such as anti-acarid body wash, anti-acarid facial cleaners and anti-acarid daily chemi...  
WO/2020/047198A1
The present invention relates to processes and intermediates for preparing 3-(cyanomethyl)-3-(4-{[(IR,2S)-2- phenylcyclopropyl]amino}piperi din-l-yl)azeti dine-1-sulfonamide, and salts and solid forms thereof, which selectively modulate ...  
WO/2020/039092A2
The present invention comprises novel aromatic molecules, which can be used in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders such as disorders of the haemat...  
WO/2020/039088A2
The present invention comprises novel aromatic molecules, which can be used in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders such as disorders of the haemat...  
WO/2020/041100A1
Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein...  
WO/2020/041384A1
3-Phenyl-2-cyano-azetidine derivatives and methods are provided for the inhibition of the function of RNA guided endonucleases, including the identification and use of such inhibitors. Methods of identifying inhibitor compounds of RNA gu...  
WO/2020/035464A1
The present invention relates to compounds of formula (I): wherein Q is selected from O or S; R1 and R3 are each independently hydrogen or an optionally substituted hydrocarbyl group, or R1 and R3 together with the nitrogen atom to which...  
WO/2020/017569A1
The purpose of the present invention is to provide a novel T-type calcium channel blocker. A compound represented by general formula (I), a tautomer or stereoisomer of the compound, a pharmaceutically acceptable salt thereof or a solvate...  
WO/2019/235553A1
The present invention addresses the problem of providing a compound that is useful as a therapeutic or prophylactic for diseases related to the immune system, particularly autoimmune diseases such as systemic lupus erythematosus (SLE) an...  
WO/2019/231933A2
The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds and methods of making and using such compounds.  
WO/2019/226490A1
Provided is a compound of Formula (I), wherein the variable groups are defined herein.  
WO/2019/217977A1
Disclosed herein are compounds represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. Values for the variables in Structural Formula I are described herein. The compounds can be used to modulate (e.g, inhib...  
WO/2019/204740A1
The present disclosure provides azetidine compounds of Formula I and their pharmaceutically acceptable salts, their compositions, and methods for their use in determining azetidine compound binding to proteins. The azetidine compounds ar...  
WO/2019/200131A1
The present disclosure provides methods related to treating triple-negative breast cancer (TNBC) in a mammal by administering salvianolic acid B (or a salt or solvate thereof) to promote ceramide-mediated apoptosis. In one form, the cera...  
WO/2019/183589A1
The present disclosure relates generally to eukaryotic initiation factor 2B modulators of formula A, or a pharmaceutically acceptable salt, stereoisomer, or mixture of stereoisomers thereof and methods of making and using thereof.  
WO/2019/182924A1
Janus kinases (JAKs) inhibitors have Formula (I).  
WO/2019/163917A1
Provided is a compound in which the balance of the agonist activity against the S1P5 receptor relative to the S1P1 receptor has been improved in order to develop a pharmaceutical useful for the treatment of S1P5-mediated diseases such as...  
WO/2019/159168A1
The present invention provides cannabinoid derivatives, more specifically cannabidiol (CBD), desoxy-CBD, and desoxy-A9- tetrahydrocannabinol (desoxy-THC) derivatives, which are useful for neuroprotection, treating pain, or treating a dis...  
WO/2018/119362A8
Provided herein are compounds and methods for inhibiting histone deacetylase ("HDAC") enzymes (e.g., HDAC1, HDAC2, and HDAC3).  
WO/2019/154288A1
Disclosed in the present invention are a cationic compound, a preparation method therefor and a use thereof. Provided by the present invention is a compound represented by formula I having a novel structure, or a pharmaceutically accepta...  
WO/2019/154287A1
Disclosed are a quaternary ammonium salt compound, a preparation method therefor and a use thereof. Provided is a novel structural compound as shown in formula Ⅰ, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof...  
WO/2019/144094A1
Disclosed crystalline Siponimod fumaric acid, solid state forms (polymorphs) thereof, processes for preparation thereof and pharmaceutical compositions thereof.  
WO/2019/101150A1
An HS-25 tablet, an HS-25 solid dispersion composition, a preparation method therefor and usage thereof. The HS-25 tablet is made by using HS-25 and excipients for wet granulation, drying, granulating and tablet pressing.  

Matches 1 - 50 out of 4,695